Teva Pharmaceutical Industries Ltd SEC filings TEVA
Teva Pharmaceutical Industries Ltd has 1,001 filings in SEC EDGAR's recent list, going back to Oct 17, 2017. Its latest annual report, Form ARS, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-A12B/A | Filing | Sep 14, 2026 | — |
| 25-NSE | Delisting notice | Sep 14, 2026 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 2, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2025 | — |
| SD | Specialized disclosure (conflict minerals) | May 30, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2024 | — |
| SD | Specialized disclosure (conflict minerals) | May 24, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2022 | — |
| CORRESP | Letter to the SEC | Dec 20, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 1, 2022 | — |
| CORRESP | Letter to the SEC | Oct 26, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2022 | — |
| SD | Specialized disclosure (conflict minerals) | May 25, 2022 | — |
| SD | Specialized disclosure (conflict minerals) | May 20, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2021 | — |
| CORRESP | Letter to the SEC | Apr 15, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2021 | — |
| EFFECT | Filing | Aug 17, 2020 | — |
| SD | Specialized disclosure (conflict minerals) | Aug 14, 2020 | — |
| CORRESP | Letter to the SEC | Aug 13, 2020 | — |
| CORRESP | Letter to the SEC | Aug 13, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2020 | — |
| CORRESP | Letter to the SEC | Jun 19, 2020 | — |
| CORRESP | Letter to the SEC | Apr 17, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2020 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2019 | — |
| EFFECT | Filing | Dec 3, 2018 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2018 | — |
| EFFECT | Filing | Apr 19, 2018 | — |
| EFFECT | Filing | Apr 19, 2018 | — |
| CORRESP | Letter to the SEC | Apr 16, 2018 | — |
| CORRESP | Letter to the SEC | Apr 16, 2018 | — |
| CORRESP | Letter to the SEC | Apr 16, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2018 | — |
| CORRESP | Letter to the SEC | Feb 16, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2018 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TEVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Large accelerated filer
- SEC CIK
- 818686
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED (until Jan 16, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.